Bioorganic and Medicinal Chemistry Letters

ISSN 0960-894X

Publisher: Elsevier

Related content

By this: publisher
In this subject: Anatomy & Physiology

Volume 14, Number 4, 23 February 2004

Editorial Board
pp. CO2-CO2(1)

Contributors to this issue
pp. I-II(2)

Graphical Contents List
pp. 823-835(13)

Effective irreversible alkylating reagents based on the structure of clavulones
pp. 837-840(4)
Authors: Tanaka H.; Kitade M.; Iwashima M.; Iguchi K.; Takahashi T.

Kringle 5 peptide-albumin conjugates with anti-migratory activity
pp. 841-845(5)
Authors: Leger R.; Benquet C.; Huang X.; Quraishi O.; van Wyk P.; Bridon D.

Mass-tag technology for monitoring of protein kinase activity using mass spectrometry
pp. 847-850(4)
Authors: Sonoda T.; Shigaki S.; Nagashima T.; Okitsu O.; Kita Y.; Murata M.; Katayama Y.

A neural network based prediction of octanol-water partition coefficients using atomic5 fragmental descriptors
pp. 851-853(3)
Authors: Molnar L.; Keseru G.M.; Papp A.; Gulyas Z.; Darvas F.

Miraziridine A: natures blueprint towards protease class-spanning inhibitors
pp. 855-857(3)
Author: Schaschke N.

Diastereoselective synthesis and configuration-dependent activity of (3-substituted-cycloalkyl)glycine pyrrolidides and thiazolidides as dipeptidyl peptidase IV inhibitors
pp. 859-863(5)
Authors: Ashton W.T.; Dong H.; Sisco R.M.; Doss G.A.; Leiting B.; Patel R.A.; Wu J.K.; Marsilio F.; Thornberry N.A.; Weber A.E.

3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2
pp. 865-868(4)
Authors: Sheppard G.S.; Wang J.; Kawai M.; BaMaung N.Y.; Craig R.A.; Erickson S.A.; Lynch L.; Patel J.; Yang F.; Searle X.B.; Lou P.; Park C.; Kim K.H.; Henkin J.; Lesniewski R.

Carbonic anhydrase inhibitors: The first selective, membrane-impermeant inhibitors targeting the tumor-associated isozyme IX
pp. 869-873(5)
Authors: Pastorekova S.; Casini A.; Scozzafava A.; Vullo D.; Pastorek J.; Supuran C.T.

Orally active anti-proliferation agents: novel diphenylamine derivatives as FGF-R2 autophosphorylation inhibitors
pp. 875-879(5)
Authors: Shimizu T.; Fujiwara Y.; Osawa T.; Sakai T.; Kubo K.; Kubo K.; Nishitoba T.; Kimura K.; Senga T.; Murooka H.; Iwai A.; Fukushima K.; Yoshino T.; Miwa A.

Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates
pp. 881-885(5)
Authors: Zloh M.; Kaatz G.W.; Gibbons S.

Obtaining higher transesterification rates with subtilisin Carlsberg in nonaqueous media
pp. 887-889(3)
Authors: Roy I.; Sharma A.; Gupta M.N.

Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)
pp. 891-895(5)
Authors: Tjernberg A.; Hallen D.; Schultz J.; James S.; Benkestock K.; Bystrom S.; Weigelt J.

Predicting pharmacophore signals for post-coital antifertility activity of 1-trifluoromethyl-1,2,2-triphenylethylene derivatives: a statistical approximation using E-state index
pp. 897-900(4)
Authors: Mukherjee S.; Mukherjee A.; Saha A.

Synthesis and biological evaluation of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) C8 cyclic amine conjugates
pp. 901-904(4)
Authors: Masterson L.A.; Croker S.J.; Jenkins T.C.; Howard P.W.; Thurston D.E.

A highly toxic morphine-3-glucuronide derivative
pp. 905-908(4)
Authors: Salvatella M.; Arsequell G.; Valencia G.; Rodriguez R.E.

Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR
pp. 909-912(4)
Authors: Wu Z.; Fraley M.E.; Bilodeau M.T.; Kaufman M.L.; Tasber E.S.; Balitza A.E.; Hartman G.D.; Coll K.E.; Rickert K.; Shipman J.; Shi B.; Sepp-Lorenzino L.; Thomas K.A.

A new series of potent oxindole inhibitors of CDK2
pp. 913-917(5)
Authors: Luk K.-C.; Simcox M.E.; Schutt A.; Rowan K.; Thompson T.; Chen Y.; Kammlott U.; DePinto W.; Dunten P.; Dermatakis A.

Benzimidazolone p38 inhibitors
pp. 919-923(5)
Authors: Dombroski M.A.; Letavic M.A.; McClure K.F.; Barberia J.T.; Carty T.J.; Cortina S.R.; Csiki C.; Dipesa A.J.; Elliott N.C.; Gabel C.A.; Jordan C.K.; Labasi J.M.; Martin W.H.; Peese K.M.; Stock I.A.; Svensson L.; Sweeney F.J.; Yu C.H.

Epimerisation of lutein to 3'-epilutein in processed foods
pp. 925-928(4)
Authors: Deli J.; Molnar P.; Osz E.; Toth G.; Zsila F.

Regioselective oxidation of 2-amino-3-aroyl-4,5-dialkylthiophenes by DMSO
pp. 929-933(5)
Authors: Joshi E.; Chordia M.D.; Macdonald T.L.; Linden J.; Olsson R.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains
pp. 935-939(5)
Authors: Shen D.-M.; Shu M.; Mills S.G.; Chapman K.T.; Malkowitz L.; Springer M.S.; Gould S.L.; DeMartino J.A.; Siciliano S.J.; Kwei G.Y.; Carella A.; Carver G.; Holmes K.; Schleif W.A.; Danzeisen R.; Hazuda D.; Kessler J.; Lineberger J.; Miller M.D.; Emini E.A.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds
pp. 941-945(5)
Authors: Shen D.-M.; Shu M.; Willoughby C.A.; Shah S.; Lynch C.L.; Hale J.J.; Mills S.G.; Chapman K.T.; Malkowitz L.; Springer M.S.; Gould S.L.; DeMartino J.A.; Siciliano S.J.; Lyons K.; Pivnichny J.V.; Kwei G.Y.; Carella A.; Carver G.; Holmes K.; Schleif W.A.; Danzeisen R.; Hazuda D.; Kessler J.; Lineberger J.; Miller M.D.; Emini E.A.

Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment
pp. 947-952(6)
Authors: Shu M.; Loebach J.L.; Parker K.A.; Mills S.G.; Chapman K.T.; Shen D.-M.; Malkowitz L.; Springer M.S.; Gould S.L.; DeMartino J.A.; Siciliano S.J.; Salvo J.D.; Lyons K.; Pivnichny J.V.; Kwei G.Y.; Carella A.; Carver G.; Holmes K.; Schleif W.A.; Danzeisen R.; Hazuda D.; Kessler J.; Lineberger J.; Miller M.D.; Emini E.A.

Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles
pp. 953-957(5)
Authors: Wood E.R.; Kuyper L.; Petrov K.G.; Hunter R.N.; Harris P.A.; Lackey K.

Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains
pp. 959-963(5)
Authors: Miller J.F.; Furfine E.S.; Hanlon M.H.; Hazen R.J.; Ray J.A.; Robinson L.; Samano V.; Spaltenstein A.

Lysyl 4-aminobenzoic acid derivatives as potent small molecule mimetics of plasminogen kringle 5
pp. 965-966(2)
Authors: Sheppard G.S.; Kawai M.; Craig R.A.; Davidson D.J.; Majest S.M.; Bell R.L.; Henkin J.

Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency
pp. 967-971(5)
Authors: Beaulieu P.L.; Bos M.; Bousquet Y.; DeRoy P.; Fazal G.; Gauthier J.; Gillard J.; Goulet S.; McKercher G.; Poupart M.-A.; Valois S.; Kukolj G.

Novel inhibitors of fatty acid oxidation as potential metabolic modulators
pp. 973-977(5)
Authors: Elzein E.; Shenk K.; Ibrahim P.; Marquart T.; Kerwar S.; Meyer S.; Ahmed H.; Zeng D.; Chu N.; Soohoo D.; Wong S.; Leung K.; Zablocki J.

Synthesis and evaluation of S-4-(3-thienyl)phenyl--methylacetic acid
pp. 979-982(4)
Authors: Mittal S.; Malde A.; Selvam C.; Arun K.H.S.; Johar P.S.; Jachak S.M.; Ramarao P.; Bharatam P.V.; Chawla H.P.S.

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs
pp. 983-987(5)
Authors: Zhang P.; Bao L.; Zuckett J.F.; Goldman E.A.; Jia Z.J.; Arfsten A.; Edwards S.; Sinha U.; Hutchaleelaha A.; Park G.; Lambing J.L.; Hollenbach S.J.; Scarborough R.M.; Zhu B.-Y.

Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity
pp. 989-993(5)
Authors: Zhang P.; Bao L.; Zuckett J.F.; Jia Z.J.; Woolfrey J.; Arfsten A.; Edwards S.; Sinha U.; Hutchaleelaha A.; Lambing J.L.; Hollenbach S.J.; Scarborough R.M.; Zhu B.-Y.

4-Thio-5-bromo-2'-deoxyuridine: chemical synthesis and therapeutic potential of UVA-induced DNA damage
pp. 995-997(3)
Authors: Xu Y.-Z.; Zhang X.; Wu H.-C.; Massey A.; Karran P.

Binding of -carbolines at imidazoline I₂ receptors: a structure-affinity investigation
pp. 999-1002(4)
Authors: Glennon R.A.; Grella B.; Tyacke R.J.; Lau A.; Westaway J.; Hudson A.L.

Pyrazino[1,2-a]indoles as novel high-affinity and selective imidazoline I₂ receptor ligands
pp. 1003-1005(3)
Authors: Chang-Fong J.; Tyacke R.J.; Lau A.; Westaway J.; Hudson A.L.; Glennon R.A.

Doxorubicin prodrug on the basis of tert-butyl cephalosporanate sulfones
pp. 1007-1010(4)
Authors: Veinberg G.; Shestakova I.; Vorona M.; Kanepe I.; Domrachova I.; Lukevics E.

Anti-inflammatory flavonoids and pterocarpanoid from Crotalaria pallida and C. assamica
pp. 1011-1014(4)
Authors: Ko H.-H.; Weng J.-R.; Tsao L.-T.; Yen M.-H.; Wang J.-P.; Lin C.-N.

Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate
pp. 1015-1017(3)
Authors: Maeda N.; Takeuchi Y.; Takada M.; Namba Y.; Oku N.

Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids
pp. 1019-1022(4)
Authors: Roy U.; Loreau O.; Balazy M.

4-Substituted anilides as selective melatonin MT₂ receptor agonists
pp. 1023-1026(4)
Authors: Epperson J.R.; Deskus J.A.; Gentile A.J.; Iben L.G.; Ryan E.; Sarbin N.S.

N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F₁F₀ ATP hydrolase
pp. 1027-1030(4)
Authors: Atwal K.S.; Ahmad S.; Ding C.Z.; Stein P.D.; Lloyd J.; Hamann L.G.; Green D.W.; Ferrara F.N.; Wang P.; Rogers W.L.; Doweyko L.M.; Miller A.V.; Bisaha S.N.; Schmidt J.B.; Li L.; Yost K.J.; Lan H.-J.; Madsen C.S.

Benzodiazepine-based selective inhibitors of mitochondrial F₁F₀ ATP hydrolase
pp. 1031-1034(4)
Authors: Hamann L.G.; Ding C.Z.; Miller A.V.; Madsen C.S.; Wang P.; Stein P.D.; Pudzianowski A.T.; Green D.W.; Monshizadegan H.; Atwal K.S.

1,2-Benzothiazine 1,1-dioxide -ketoamide analogues as potent calpain I inhibitors
pp. 1035-1038(4)
Authors: Bihovsky R.; Tao M.; Mallamo J.P.; Wells G.J.

The development of potent non-peptidic PTP-1B inhibitors
pp. 1039-1042(4)
Authors: Dufresne C.; Roy P.; Wang Z.; Asante-Appiah E.; Cromlish W.; Boie Y.; Forghani F.; Desmarais S.; Wang Q.; Skorey K.; Waddleton D.; Ramachandran C.; Kennedy B.P.; Xu L.; Gordon R.; Chan C.C.; Leblanc Y.

Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors
pp. 1043-1048(6)
Authors: Lau C.K.; Bayly C.I.; Gauthier J.Y.; Li C.S.; Therien M.; Asante-Appiah E.; Cromlish W.; Boie Y.; Forghani F.; Desmarais S.; Wang Q.; Skorey K.; Waddleton D.; Payette P.; Ramachandran C.; Kennedy B.P.; Scapin G.

Non-peptide _v₃ antagonists. Part 7: 3-Substituted tetrahydro-naphthyridine derivatives
pp. 1049-1052(4)
Authors: Wang J.; Breslin M.J.; Coleman P.J.; Duggan M.E.; Hunt C.A.; Hutchinson J.H.; Leu C.-T.; Rodan S.B.; Rodan G.A.; Duong L.T.; Hartman G.D.